This is a translation from a swedish press release Stockholm dated 2016-12-23. Kancera AB (publ) today announced that Joachim Forsgren (MD, PhD) has been appointed Chief Medical Officer and will be medically responsible for Kancera product portfolio. He will be part of the management team and report directly to the CEO.
Joachim Forsgren (born 1954) is a medical doctor with a PhD in medical science. He has more than 18 years of experience in clinical development from leading positions within AstraZeneca, where he was responsible for clinical development and patient safety issues, for example in the role of Site Head of Clinical Development, AstraZeneca R & D Södertälje. Most recently, Joachim held the position of Vice President, Global Head of Patient Safety, AstraZeneca R & D.
"We are very pleased to welcome Joachim Forsgren to Kancera. He has extensive international experience in clinical drug development. The recruitment of Joachim is especially important at this time when we are in an intensive phase of planning for our upcoming clinical studies”, said Thomas Olin, CEO of Kancera AB.
"I look forward to helping to take Kancera’s promising treatment concept into the clinical phase and working with the company's innovative experts to significantly improve the care of critically ill patients”, says Joachim Forsgren, incoming Chief Medical Officer of Kancera AB.
About Kancera AB (publ)
Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, based on blocking survival signals in the cancer cell and on addressing cancer metabolism. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 15 people. Kancera shares are traded on NASDAQ First North and the number of shareholders were about 7800 as of October 14th, 2016. FNCA is Kancera’s Certified Adviser. Professor Carl-Henrik Heldin, Professor Håkan Mellstedt, and MD PhD Charlotte Edenius are board members and Kancera´s scientific advisers.
For further information please contact,
Thomas Olin, VD: 0735-20 40 01
Kancera AB (publ)
Karolinska Institutet Science Park
SE 171 48 Solna
Visit our home page at: http://www.kancera.com